Literature DB >> 9840695

Diagnosis and management of venous thrombosis in the surgical patient.

M R Jackson1.   

Abstract

Deep venous thrombosis (DVT) continues to be a source of major morbidity and mortality for surgical patients. The incidence of postoperative DVT is as high as 28% in some series. Risk factors include immobility, venous endothelial injury, stasis, and advanced age, all of which are highly prevalent in many populations of surgical patients. Diagnosis is generally confirmed by using duplex ultrasound to examine the legs. This modality has largely replaced contrast venography as the gold standard imaging test for DVT. Treatment begins with heparin and warfarin. Recently, low-molecular-weight heparin (LMWH) has been shown to be a suitable alternative to conventional, unfractionated heparin as the initial anticoagulant treatment of DVT. This change permits outpatient treatment of DVT in suitable patients. However, anticoagulation is contraindicated in many postoperative patients, who may then require an inferior vena caval filter. Iliofemoral venous thrombectomy should be considered when postoperative patients present with phlegmasia cerulea dolens. Long-term management of these patients focuses on measures to prevent clinical manifestations of chronic venous insufficiency.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9840695

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  2 in total

1.  Deep vein thrombosis and pulmonary embolism in cirrhosis patients.

Authors:  David Gulley; Evgenia Teal; Attaya Suvannasankha; Naga Chalasani; Suthat Liangpunsakul
Journal:  Dig Dis Sci       Date:  2008-04-29       Impact factor: 3.199

2.  Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacement.

Authors:  Takafumi Torigoshi; Satoru Motokawa; Yumi Maeda; Kazushige Maeda; Takeshi Hiura; Gou Takayama; Kenji Taguchi; Hiroyuki Shindo; Kiyoshi Migita
Journal:  BMC Musculoskelet Disord       Date:  2009-04-28       Impact factor: 2.362

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.